Product Images Valsartan

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 6 images provide visual information about the product associated with Valsartan NDC 42291-858 by Avkare, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

40 - 856 30 40mg

40 - 856  30 40mg

This is a description of a medicine with the NDC code 42291-856.30. Each tablet contains 0 mg of Valsartan, USP. The dosage and administration details are not available. The text mentions keeping the tablets and all drugs out of reach of children. The manufacturer of these tablets is "Aniesl Pharmaceuticals of Y, LLC." The medicine is only manufactured for ARCRE, Push TN 56478, and AVKKRE o Pz SO.*

80 - 857 90 80mg

80 - 857 90 80mg

160 - 858 90 160mg

160 - 858 90 160mg

This is a description of a medication with the NDC code 42201-858-90. Each tablet contains 160 mg of valsartan. The medication is packaged in a container with 90 tablets. It is manufactured by Amneal Pharmaceuticals of Brookhaven, New York, and it is distributed by AKARE of Pulaski, Tennessee. The container should be stored at a controlled room temperature and protected from moisture. The text includes a note to keep all drugs out of reach of children.*

320 - 859 90 320mg

320 - 859 90 320mg

Each tablet of DG 42291-859-00 contains 20mg of Valsartan, USP. These tablets are used in the treatment of hypertension and heart failure. They should be stored at controlled room temperature and tightly closed in their container to protect from moisture. The medication is manufactured by Amneal Pharmaceuticals and distributed by AKARE.*

f9674dc4-figure-01 - valsartan tablets usp 1

f9674dc4-figure-01 - valsartan tablets usp 1

1 - valsartan tablets usp 2

1 - valsartan tablets usp 2

The text provides a table showing the percentage of patients in different subgroups in the VALIAN study and how different medications affected mortality. The study evaluated the effects on mortality for patients under and over 65 years old, male and female, Caucasian and Non-Caucasian, and the use of a beta-blocker. The table shows that valsartan favors over captopril in reducing mortality.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.